Figure 1: Meta-analysis of height at baseline, after 12, 24 or 36 months of recombinant human growth hormone treatment until final height in patients with Noonan syndrome. (A) baseline; (B) 12 months; (C) 24 months; (D) 36 months; (E) final height. Each included study is represented by one square while square area is proportional to sample size (i.e. patient amount). The horizontal lines represent the confidence intervals (95%CI) while the vertical lines crossing zero value (i.e. the no-effect vertical line) mean the absence of significant difference (e.g. no treatment effect). If the study square or its horizontal line overlap the no-effect vertical line, there is no statistical significance. The meta-analysis summary measure is reported at the bottom of the left side, corresponding to a diamond or small vertical bar. If the diamond does not cross the no-effect vertical line, the result of the meta-analysis is statistically significant. The values (difference in means, p-values, confidence intervals, etc.) are indicated between the study names and the graphic.